SCHEMBL4876689

SCHEMBL4876689

CN1CCC(Sc2ccc(NS(=O)(=O)c3ccc(Cl)cc3)cc2)CC1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CES1 P23141 1/20 0.54
HTR2A P28223 6/20 0.53
HTR2C P28335 6/20 0.53
DRD2 P14416 5/20 0.53
DRD3 P35462 5/20 0.53
HTR6 P50406 5/20 0.53
CYP1A2 P05177 1/20 0.53
CYP3A4 P08684 1/20 0.53
CYP2D6 P10635 1/20 0.53
CYP2C9 P11712 1/20 0.53
CYP2C19 P33261 1/20 0.53
KMT2A Q03164 1/20 0.52
ALDH1A1 P00352 3/20 0.48
TDP1 Q9NUW8 1/20 0.48
PKM P14618 1/20 0.47
L3MBTL1 Q9Y468 1/20 0.45
PRMT1 Q99873 1/20 0.45
POLB P06746 1/20 0.45
HDAC3 O15379 1/20 0.44
HDAC4 P56524 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4866321 0.89 ALDH1A1 (0.57) KMT2AALDH1A1TDP1L3MBTL1POLB
SCHEMBL4874458 0.89 ALDH1A1 (0.44) HTR2AHTR2CDRD2DRD3HTR6
SCHEMBL4876786 0.88 ALDH1A1 (0.56) HTR2AHTR2CDRD2DRD3HTR6
SCHEMBL4876385 0.88 HTR6 (0.49) HTR2AHTR2CDRD2DRD3HTR6
SCHEMBL4873695 0.88 ALDH1A1 (0.58) HTR2AHTR2CCYP3A4CYP2C9KMT2A
SCHEMBL4868720 0.87 MAPT (0.49) HTR2AHTR2CDRD2DRD3HTR6
SCHEMBL4874044 0.86 ALDH1A1 (0.62) HTR2AHTR2CDRD2DRD3HTR6
SCHEMBL6617076 0.86 ALDH1A1 (0.60) KMT2AALDH1A1TDP1PKMMAPT
SCHEMBL4876622 0.85 ALDH1A1 (0.60) CYP3A4KMT2AALDH1A1TDP1PKM
SCHEMBL4869725 0.82 HTR2A (0.51) HTR2ADRD2DRD3HTR6ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7408067-B2 Aza-cyclic compounds as modulators of acetylcholine receptors MERCK + CO., INC. (US) 2008-08-05 US disclosed
US-20050070520-A1 Aza-cyclic compounds as modulators of acetylcholine receptors MERCK SHARP & DOHME CORP. 2005-03-31 US disclosed
EP-1467986-A1 AZA-CYCLIC COMPOUNDS AS MODULATORS OF ACETYLCHOLINE RECEPTORS ELI LILLY AND COMPANY (US) 2004-10-20 EP disclosed
WO-2003062224-A1 AZA-CYCLIC COMPOUNDS AS MODULATORS OF ACETYLCHOLINE RECEPTORS ELI LILLY AND COMPANY (US) 2003-07-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050070520-A1 Aza-cyclic compounds as modulators of acetylcholine receptors CHRNG, CHRNA4, CHRNB4 CES1 1820/4885HTR2A 529/4885HTR2C 439/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.